Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Pharma Strategy Will Remove Barriers And Bolster Competition

Proposals Promise ‘Targeted Policies’ To Boost Generics And Biosimilars

Executive Summary

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

You may also be interested in...



European Parliament Urges Increased Role For Generics And Biosimilars

A report adopted by the European Parliament calling for measures to support a “greater market presence for generic and biosimilar medicines” has been welcomed by Medicines for Europe.

Sandoz Invests In Its Unique Antibiotics Offering

In the wake of a major deal to acquire GlaxoSmithKline’s cephalosporins business, Sandoz CEO Richard Saynor has set out why the company’s unique position means that antibiotics are an important area for investments, in an exclusive interview with Generics Bulletin.

Off-Patent Industry Must Become ‘Focal Point’ For Health Systems Post-COVID

Off-patent medicines must become the “focal point” of pharmaceutical policies across the world as health systems recover from the COVID-19 pandemic, Medicines for Europe and the IGBA have urged as they held their joint annual conference in Athens, Greece.

Related Content

Topics

UsernamePublicRestriction

Register

GB150464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel